ClinicaliQ Trial Snapshot
- The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) — Recruiting • Phase III • Oncology • NCT06520345.
- What is being tested: 177Lu-TLX591, a targeted radioligand therapy, is being evaluated in combination with standard of care versus standard of care alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on androgen receptor pathway inhibitors.
- Patient eligibility overview: The trial includes patients with mCRPC who have demonstrated disease progression despite prior treatment with androgen receptor pathway inhibitors (such as abiraterone or enzalutamide), representing an advanced, treatment-resistant population with limited therapeutic options.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Eligibility Snapshot
- : * Be a male, at least 18 years old, with documented adenocarcinoma of the prostate defined by histological / pathological confirmation. * Be of ECOG Performance Status 0, 1, or 2 and have an estimated life expectancy of ≥6 months from Day 1. * Have metastatic disease (defined as ≥1 metastatic lesion present on baseline CT, MRI or bone scintigraphy). * Have castration-resistant PC (defined as disease progressing despite castration by orchiectomy or ongoing use of luteinizing hormone-releasing hormone [LHRH] analogues) and must have a castrate level of serum/plasma testosterone (
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.